SynthesisWorld journal of surgical oncology2021
A systematic review of proteomic biomarkers in oral squamous cell cancer.
Synthesis in World journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 70 citations in OpenAlex.
- Tumor Biomarkers in Head and Neck Squamous Cell Carcinoma: From Etiology and Pathogenesis to Treatment Response-A Scoping Review.Biomedicines · 2026Review
- New genomic and proteomic biomarker discovery in cancer: revolutionizing diagnosis and prognostication.World journal of surgical oncology · 2026Review
- Analysis of Soft Tissue N-Glycome Profiles in Oral Squamous Cell Carcinoma, a Pilot Study.International journal of molecular sciences · 2026Article
- NCOA7 promotes OSCC progression by inhibiting ROS-regulated ferroptosis.Cellular and molecular life sciences : CMLS · 2026Article
- The potential of cytokine polymorphisms as biomarkers for oral squamous cell carcinoma: a systematic review.Discover oncology · 2026Review
- Hypoxia-regulated non-coding RNAs in OSCC liquid biopsy: from molecular mechanisms to AI-driven precision oncology.Frontiers in oncology · 2026Review
- In Silico Analysis of Squamous Cell Carcinoma.Advances in experimental medicine and biology · 2026Review
- Proteomic identification and histopathological validation of candidate biomarkers CA1, HBB, Torsin A, andFrontiers in medicine · 2026Article
- Evaluating palmitoyl-protein thioesterase 1 in oral squamous cell carcinoma: A novel indicator of tumor behavior and therapeutic response.World journal of experimental medicine · 2025Article
- DNMT1 modulation of RASSF1A methylation enhances breast cancer brain metastasis.Cell death & disease · 2025Article
- Review
- Cell-Free DNA as a Prognostic Biomarker in Oral Carcinogenesis and Oral Squamous Cell Carcinoma: A Translational Perspective.Cancers · 2025Review
- An Automated Approach to Analyze MMP1 Expression in Oral Squamous Cell Carcinoma Using Fluorescence in Situ Hybridization: An Image Based Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Loc646329 sponges miR-21 to reduce RAS/MAP kinase signaling pathway in oral squamous cell carcinoma (OSCC).Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Perspectives on the Application of Biosensors for the Early Detection of Oral Cancer.Sensors (Basel, Switzerland) · 2025Review
- Deep Saliva Proteomics Elucidating the Pathogenesis of Early Childhood Caries and Identifying Biomarkers for Early Prediction.Journal of proteome research · 2025Article
- Recent advances in biomarker detection of oral squamous cell carcinoma.Frontiers in oncology · 2025Review
- TRAIP enhances progression of tongue squamous cell carcinoma through EMT and Wnt/β-catenin signaling by interacting with DDX39A.BMC cancer · 2024Article
- Biological biomarkers of oral cancer.Periodontology 2000 · 2024Review
- Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell cancer (HNSCC) is the most common cancer associated with chewing tobacco, in the world. As this is divided in to sites and subsites, it does not make it to top 10 cancers. The most common subsite is the oral cancer. At the time of diagnosis, more than 50% of patients with oral squamous cell cancers (OSCC) had advanced disease, indicating the lack of availability of early detection and risk assessment biomarkers. The new protein biomarker development and discovery will aid in early diagnosis and treatment which lead to targeted treatment and ultimately a good prognosis.
methodsThis systematic review was performed as per PRISMA guidelines. All relevant studies assessing characteristics of oral cancer and proteomics were considered for analysis. Only human studies published in English were included, and abstracts, incomplete articles, and cell line or animal studies were excluded.
resultsA total of 308 articles were found, of which 112 were found to be relevant after exclusion. The present review focuses on techniques of cancer proteomics and discovery of biomarkers using these techniques. The signature of protein expression may be used to predict drug response and clinical course of disease and could be used to individualize therapy with such knowledge.
conclusionsProspective use of these markers in the clinical setting will enable early detection, prediction of response to treatment, improvement in treatment selection, and early detection of tumor recurrence for disease monitoring. However, most of these markers for OSCC are yet to be validated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.